首页期刊导航|中国结合医学杂志(英文版)
期刊信息/Journal information
中国结合医学杂志(英文版)
中国结合医学杂志(英文版)

陈可冀

月刊

1672-0415

cjim@cjim.cn,

010-62877592

100091

北京西苑操场1号

中国结合医学杂志(英文版)/Journal Chinese Journal of Integrative MedicineCSCDCSTPCD北大核心SCI
查看更多>>本刊主要宣传党的中医政策和中西医结合方针,报道我国中西医结合在临床、科研、预防、教学等方面的经验和成果,探讨中西医结合的思路和方法,介绍国内外有关本专业的进展,开展学术讨论,为提高西医结合水平、继承和发扬我国传统的医药学、促进我国医学科学现代化服务。
正式出版
收录年代

    Advancements of Macrophages Involvement in Pathological Progression of Colitis-Associated Colorectal Cancer and Associated Pharmacological Interventions

    KE Jun-yuSONG Jin-binLI LongHE Zhen-fan...
    565-576页
    查看更多>>摘要:Intestinal macrophages play crucial roles in both intestinal inflammation and immune homeostasis.They can adopt two distinct phenotypes,primarily determined by environmental cues.These phenotypes encompass the classically activated pro-inflammatory M1 phenotype,as well as the alternatively activated anti-inflammatory M2 phenotype.In regular conditions,intestinal macrophages serve to shield the gut from inflammatory harm.However,when a combination of genetic and environmental elements influences the polarization of these macrophages,it can result in an M1/M2 macrophage activation imbalance,subsequently leading to a loss of control over intestinal inflammation.This shift transforms normal inflammatory responses into pathological damage within the intestines.In patients with ulcerative colitis-associated colorectal cancer(UC-CRC),disorders related to intestinal inflammation are closely correlated with an imbalance in the polarization of intestinal M1/M2 macrophages.Therefore,reinstating the equilibrium in M1/M2 macrophage polarization could potentially serve as an effective approach to the prevention and treatment of UC-CRC.This paper aims to scrutinize the clinical evidence regarding Chinese medicine(CM)in the treatment of UC-CRC,the pivotal role of macrophage polarization in UC-CRC pathogenesis,and the potential mechanisms through which CM regulates macrophage polarization to address UC-CRC.Our objective is to offer fresh perspectives for clinical application,fundamental research,and pharmaceutical advancement in UC-CRC.